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ABSTRACT
Objectives: To investigate attention deficit and
hyperactivity disorder (ADHD) drug prescribing in
children under 16 years old in the UK between 1992
and 2013.
Methods: All patients under 16 registered in the
Clinical Practice Research Datalink (CPRD) with a
minimum of 1 year of observation time and who
received at least one prescription of any ADHD drug
between 1 January 1992 and 31 December 2013.
Trends in prevalence and incidence of use of ADHD
drugs in children were calculated between 1995 and
2013 and persistence in new users was estimated.
Results: The prevalence of ADHD drug use in children
under 16 increased 34-fold overall, rising from 1.5
95% CI (1.1 to 2.0) per 10 000 children in 1995 to
50.7 95% CI (49.2 to 52.1) per 10 000 children in
2008 then stabilising to 51.1 95% CI (49.7 to 52.6)
per 10 000 children in 2013. The rate of new users
increased eightfold reaching 10.2 95% CI (9.5 to 10.9)
per 10 000 children in 2007 then decreasing to 9.1
95% CI (8.5 to 9.7) per 10 000 children in 2013.
Although prevalence and incidence increased rather
steeply after 1995, this trend seems to halt from 2008
onwards. We identified that 77%, 95% CI (76% to
78%) of children were still under treatment after 1 year
and 60% 95% CI (59% to 61%) after 2 years.
Conclusions: There was a marked increase in ADHD
drug use among children in the UK from 1992 until
around 2008, with stable levels of use since then. UK
children show relatively long persistence of treatment
with ADHD medications compared to other countries.
INTRODUCTION
Attention deﬁcit and hyperactivity disorder
(ADHD) is an early onset neurodevelopmen-
tal disorder combining overactivity and
impulsivity with the inability to concentrate
(The International Classiﬁcation of Diseases
(ICD) 10th edition criteria).1 Its worldwide
prevalence was recently estimated at 5.29%
in children.2 The consequences of ADHD
can seriously impact quality of life affecting
social behaviour and health of the child but
also affect family relationships.3 Common
therapeutic options include parental train-
ing, behavioural therapies and medication.
Used since the 1960s, medications for ADHD
are currently part of the “WHO list of essen-
tial medicines for common psychiatric disor-
ders” which sets standards for medicines
worldwide, including use in children.
Methylphenidate and dexamphetamine were
the ﬁrst stimulant medications with proven
efﬁcacy in the treatment of core ADHD
symptoms.4 Increase in the use of ADHD
drugs has been observed in many studies
worldwide.5 6 During the past decade, new
guidelines were issued, new pharmacological
options were released and suspicions of
serious cardiac long-term effects were
raised.7 This study aims to give an overview
of the current use of ADHD medications in
children under 16 and its recent evolution in
the UK. Our work describes the prevalence
and incidence of ADHD drug use in chil-
dren in the UK and estimates their persist-
ence on treatment.
METHODS
Data source: The Clinical Practice Research
Datalink (CPRD)
The Clinical Practice Research Datalink
(CPRD, formerly GPRD) is one of the
Strengths and limitations of this study
▪ This study is providing an accurate and recent
estimate of the patterns of use of attention
deficit and hyperactivity disorder drugs in chil-
dren during the past decades in the UK.
▪ The Clinical Practice Research Datalink (CPRD)
has major strengths in the study of the use of
medication in children. It allows for a recent,
large, representative longitudinal cohort of chil-
dren observing current UK practice.
▪ In this study, prescribing issued from general
practitioners is described and not actual drug
dispensation or consumption by the patient.
However, a repeat of the prescription suggests
the use of medication in the UK healthcare
system.
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world’s largest databases of anonymised longitudinal
medical records from primary care since 1987. The data-
base includes data from UK GP practices that provide
high quality data on more than ﬁve million active
patients.8 The data collection is performed online and
its completeness is assessed on a regular basis with
routine checks to ensure data integrity and quality.9
Practices can only contribute data if they pass checks on
quality and then are classiﬁed as ‘Up-to-Standard’
(UTS) for research purposes. The data cover more than
8% of the population and have been shown to be
broadly representative of the UK population in terms of
demographic characteristics when compared with the
census in 2001.10 The validity of the CPRD has been
investigated in many studies demonstrating the quality of
the data available.11–13
Selection of the patients
All patients registered in the CPRD for at least 1 year in
a practice with UTS data and receiving at least one pre-
scription of an ADHD drug (see list below) before the
age of 16 between 1 January 1992 and 31 December
2013 were included. For reasons of anonymity, the
CPRD database does not give exact date of birth. Only
the year (or sometimes the month) of birth is available
for all so age estimation is imprecise. Drugs of interest
are those included in the British National Formulary
chapter 4.4 “CNS stimulants and drugs used for atten-
tion deﬁcit disorder”: methylphenidate (methylphenid-
ate ‘immediate release’ and methylphenidate ‘extended
release’), atomoxetine, dexamphetamine and modaﬁnil.
Statistical methods
Yearly prevalence was calculated dividing the number of
children under 16 receiving at least one prescription of an
ADHD drug during a year by the mid-year counts of chil-
dren under 16 registered in the database during that year.
Children were considered to receive a ﬁrst prescription if
they had a minimum of 12 months without any ADHD
drug prescription after registration in the database or were
aged below one. Yearly incidence of ADHD drug initiation
used the number of children under 16 receiving a ﬁrst pre-
scription divided by the mid-year counts of children under
16 registered in the database during that year. AWilcoxon
type non-parametric test for trend was computed to investi-
gate prescribing patterns over time.14
We also estimated persistence, deﬁned as “the dur-
ation of time from initiation to discontinuation of
therapy” according to Cramer et al.15 We therefore mea-
sured persistence considering ﬁrst prescription to ﬁrst
discontinuation for each patient. First discontinuation of
therapy was deﬁned as the ﬁrst gap of at least 90 days
with continuous registration in the CPRD between the
end of a prescription supply (approximated by the date
of last prescription+30 days) and the next prescription.
All participants were censored at the time of their last
record in the CPRD. This analysis was also performed
differentiating three groups (by age at ﬁrst prescription):
under 6 years old, 6–10 and 11–15. These were chosen
to distinguish early use (often off-label use under 6 years
for atomoxetine and methylphenidate and under 3 years
for dexamphetamine), child use (6–10 years) and early
or preadolescent use (11–15 years). The Kaplan-Meier
estimator was used for persistence rates. After checking
for proportional hazards, Cox regression was used to
compare retention in each age group to the baseline
(6–10 years). Statistical analysis used Stata Statistical
Software: Release 13.( College Station, Texas: StataCorp
LP, 2013.)
RESULTS
In our study, 14 748 children under 16 (85% boys)
received at least one prescription of an ADHD drug
between 1 January 1992 and 31 December 2013.
Methylphenidate is by far the most used drug in chil-
dren with ADHD in the UK accounting for 94% of
ADHD prescriptions followed by atomoxetine, dexamfe-
tamine and modaﬁnil (table 1).
Trends in prevalence and incidence of ADHD drug
prescription in children under 16 in the UK
Since only 13 children in the database received ADHD
drugs between 1992 and 1995, all further analyses begin
in 1995. Between 1995 and 2013, overall prevalence of
children receiving ADHD drugs increased 34-fold from
1.5/10 000 children to 50.7/10 000 children in 2008 and
then stabilises to 51.1/10 000 children in 2013 (ﬁgure 1).
Most of this increase is in methylphenidate although ato-
moxetine use increased nearly ﬁvefold from 1.5 in 2004
to 7.1/10 000 children in 2008 and then decreased to
6.3/10 000 in 2013. Most of the increase in the preva-
lence of use of ADHD drugs was observed between 1995
and 2008 for methylphenidate and atomoxetine (test for
trend in the methylphenidate rate after 2008 p=0.17; test
for trend in the atomoxetine rate after 2008 p=0.09).
Dexamfetamine and modaﬁnil show relatively low use in
children in the UK with respectively 1.3 and 0.1/10 000
children using these medications in 2013.
We identiﬁed 10 566 children (84% boys) who had at
least a year of registration in the CPRD before their ﬁrst
prescription of ADHD drug and a ﬁrst prescription of
ADHD drug between 1992 and 2013. Most children
(58%) had their ﬁrst prescription of ADHD medication
Table 1 Ranking of ADHD drug use in children under
16 years old, N=14 748: children could receive more than
one type of ADHD drug
Drug substance name Number of children (%)
Methylphenidate 13 908 (94.3)
Atomoxetine 2392 (16.2)
Dexamphetamine 581 (3.9)
Modafinil 27 (0.2)
ADHD, attention deficit and hyperactivity disorder.
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between the age of 6 and 11 (primary school age), the
majority (92%) receiving methylphenidate. The overall
incidence of ADHD drug use increased ninefold
between 1995 and 2013 from 1.1 to 9.1/10 000 children.
However, incidence of new ADHD drugs use decreased
slightly from 10.2 in 2007 to 9.1/10 000 in 2013. Again,
this pattern is mainly driven by the use of methylphenid-
ate. We can observe how methylphenidate ‘immediate
release’ use is slowly substituted by ‘extended release’
methylphenidate after 2002, after its introduction in the
UK (ﬁgure 2). Atomoxetine incidence more than
doubled in the ﬁrst 2 years of the marketing authorisa-
tion from 1.1/10 000 in 2004 to 2.5 in 2005 per 10 000
children in 2005 and then decreased to 1.6/10 000 chil-
dren by 2013.
In boys, the incidence of methylphenidate use
increased ninefold to reach 16.6/10 000 and decreased
to 14.5 in 2013. In girls, the incidence increased nine-
fold to reach 3.4/10 000 in 2007 and then remained
stable at 3.5/10 000 children until 2013 (ﬁgure 3).
Although rates of use were much higher in boys, the
proportionate increase was similar.
Prescriptions in very young children/possible off-label use
Slightly more than 6% (659) of these children received
4123 prescriptions under the licensed age (6 years old
in the UK) although 76% were issued between the ages
of 5 and 6. Of the 659 children who had a recorded ﬁrst
prescription of an ADHD drug before age six, 245
(37%) had data missing on their month of birth. As a
Figure 1 Annual prevalence rates of ADHD drugs per 10 000 children under sixteen between 1995 and 2013 in the CPRD
database, N=14, 748. Denominators are mid-year counts of children under sixteen in the CPRD. ADHD, attention deficit and
hyperactivity disorder; CPRD, Clinical Practice Research Datalink.
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sensitivity analysis, we added 6 months to their age.
We observed that 133 were still below six at the date of
their ﬁrst prescription of ADHD drug. Therefore, we
can conclude that (659–245+133) 547 (4%) of children
in our sample are likely to have been prescribed ADHD
medication below age six. While dexamphetamine is
licensed for children from 3 years only 52 children of
659 had a ﬁrst prescription aged under 6, and only two
under 3.
Persistence of ADHD drug treatment in children under 16
in the UK
We identiﬁed 1115 (11%) children of 10 566 who had
only one ADHD drug prescription and were registered
in the database for more than 3 months after this
prescription. These patients were not thought to be rep-
resentative of the majority of children treated for ADHD
and were therefore excluded from the retention analysis.
This analysis was also split into three groups, under 6,
6–10 and 11–15 years.
Our persistence analysis estimated time to the ﬁrst dis-
continuation of the treatment (no ADHD drug at least
90 days after their prescription ended). At 1 year, 77%
(95% CI 76% to 78%) of children were still taking
ADHD drugs decreasing to 60% (59–61%) after 2 years.
There was strong evidence that the probability of stop-
ping ADHD treatments within 6 years was higher in
older (11 to 15) compared to younger children (6–10),
HR=1.87 (1.77 to 1.98) (see ﬁgures 4 and 5).
DISCUSSION
Overall prevalence of ADHD drug prescribing in chil-
dren increased 34-fold and new prescribing of ADHD
drugs increased eightfold between 1995 and 2013.
However, the patterns of prevalent and incidence ADHD
drug prescribing are changing.
Figure 2 Incidence of ADHD drug initiation per 10 000 children under sixteen between 1995 and 2013 (N=10, 561) Met IR=
immediate release; Met XL=extended release. ADHD, attention deficit and hyperactivity disorder.
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Both prevalence and incidence rates started decreas-
ing from 2007 to 2008 and remain stable up to 2013.
Methylphenidate was by far the most used drug with
94% of children receiving it. Overall persistence on
ADHD medication in children receiving >1 prescription
was longer than in some countries. We found 77% (76–
78%) of children were still under treatment after 1 year.
UK rates among ADHD drug prescribing in Europe and the
USA
First, it is important to note that UK rates of ADHD
drug prescribing in children are ∼10 times lower than
US rates (0.4% UK vs 4.4% in the USA in 2005),16 two
to ﬁve times lower than Germany (0.49% in UK vs
2.21% in Germany in 2007 or 0.45% in UK vs0.9% in
Germany in 2006)17 18 and more than four times lower
than in the Netherlands (4.5 vs 19.5/1000 in 2006).6
However, UK rates are twice as high as in France (4.0
UK in our study vs 1.8/1000 children in 2005).19
Figure 3 Gender specific incidence of methylphenidate treatment initiation in children under sixteen per 10, 000 children
between 1995 and 2013, N=10, 561.
Figure 4 Time-to-discontinuation (90 days interruption) of all
ADHD treatments in children, N=9,451. ADHD, attention
deficit and hyperactivity disorder.
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Trends in ADHD drug prescribing in children, past and
recent trends
Our analysis highlights two trends in UK ADHD drug
prescribing in children. The ﬁrst a strong increase after
1995, also observed in many other studies. Several
studies reported a large increase between 1992 and 2008
in the prevalence of stimulant use in children under 18
in the UK.20 21 In the USA, the prevalence of ADHD
drug use increased from 2.8% to 4.4% between 2000
and 2005.16 France also reported rising rates of methyl-
phenidate use between 2003 and 2005 with lower abso-
lute prevalence than in the UK at 1.8/1000 children in
2005.19 In Germany, a 45% increase in prevalence of
ADHD drugs in children under 18 years was observed
between 2000 and 2007.17 Finally, a sevenfold increase of
the use of stimulants was observed in the Netherlands
between 1996 and 2006.6 Our study shows a clear break
in the increasing trend of ADHD drug prescribing in
children from 2007. Unfortunately, only few studies
report rates of ADHD medication prescribing worldwide
in children later than 2006. However, although an
1.84-fold increase in ADHD drug prescription was
observed between 1995–1996 and 2003–2004 in the
USA,22 the absolute rate of ADHD prescriptions
changed little between 2002 and 2010 and the rate of
methylphenidate use had no signiﬁcant change between
2002 and 2010.23 In addition, a study investigating
ADHD medication use in children in the US MEPS
(medical expenditure’s panel survey) shows a relatively
stable rate with 3.43% of ADHD medication use in
children in 2004 and 3.45% in 2008.24 In Germany, a
recent study shows the rate of ADHD drug prescribing
in children in DDD (deﬁned daily doses) between 1990
and 2010 using large insurance company data. They
showed a slight change in the curve from 2008 although
accurate numbers are not reported.25 As expected, the
prevalence and incidence of diagnosed ADHD in the
UK seems to follow a similar pattern from 2007.26 Stable
or decreasing trends in ADHD diagnosis were also
reported in Denmark and Germany.27 28
Why such a sudden change in prescribing patterns?
Previously, the increase in use of ADHD medications was
mainly explained by a better recognition of the issue of
the disorders,29 a more positive image of its pharmaco-
logical treatments, longer treatments going on during
adolescence and an expansion of use among girls.30 The
change in the increasing trend of ADHD drug prescrib-
ing in the UK may be explained by the UK reaching a
sufﬁcient recognition of the ADHD condition and may
mean that most children who need treatment are now
reached. Such a decrease or a ‘plateau’ may also occur
when a medication is under suspicion of severe adverse
reaction as was observed for antidepressants after warn-
ings on suicidal attempts in children was issued.31
However, the health warning on ADHD were issued only
in Canada in 2006, and referred to Adderall a drug not
marketed in the UK.32 In addition, risk warnings were
not associated with a large decline in drug prescribing
in the USA24 and further investigations on cardiac
effects did not conclude there were major risks.33 34
Such changes may also be due to the update of the
National Institute for Health and Care Excellence
(NICE) guidelines of 2008 stipulating that “Drug treat-
ment is not indicated as the ﬁrst-line treatment for all
school-age children and young people with ADHD” only
advocating the use of medication for children with
recognised ADHD and severe impairments who had pre-
viously beneﬁted from non-pharmacological therapeutic
options.35 This recommendation is different from the
recent clinical practice guidelines from the American
Academy of Pediatrics from 2011 recommending that
“school-aged children (6–11 years) should prescribe US
Food and Drug administration approved medication for
ADHD” possibly in addition to or instead of behavioural
therapy, although favouring both interventions.35
Persistence
Most studies in the literature deﬁne the persistence of
ADHD drug as time from ﬁrst prescription to the ﬁrst
discontinuation of 3–6 months. Winterstein et al22
reported that only 49.9% of children under 20 were still
receiving ADHD therapy after 1 year and 17.2% were
still taking ADHD drugs after 5 years in a sample of
Medicaid registered children in the USA. In 2001,
Schirm et al looked at duration of stimulant therapy in
Figure 5 Time-to-discontinuation (90 days interruption) of all
ADHD treatments in all children, according to the age of start
of treatment, N=9,451. ADHD, attention deficit and
hyperactivity disorder.
6 Beau-Lejdstrom R, et al. BMJ Open 2016;6:e010508. doi:10.1136/bmjopen-2015-010508
Open Access
the Netherlands from ﬁrst prescription to the ﬁrst dis-
continuation of 180 days. Half of children had stopped
their treatment after 20 months for those starting treat-
ment between 1997 and 1999.36 In Germany, only 63.9%
of boys were still taking ADHD drugs after 12 months
(time to ﬁrst discontinuation of 3 months). In our study,
UK shows the highest estimates of persistence with 77%
of children still taking ADHD drugs at 1 year, and even
with those with a single prescription included it is still
66%. This could be due to the higher prevalence of use
of ADHD medication in other countries, suggesting a
possible different approach to medicating children in
general. This may be because recommendations for
ADHD management in the UK are more stringent. Our
study shows substantially lower persistence of ADHD
medication in the older age group. This observation is
consistent with the ﬁndings that treatments may be pre-
maturely discontinued in young adults despite the latest
guidelines advising continuation of ADHD treatments as
long as they are clinically effective.37
The CPRD has major strengths in the study of the use
of medication in children.38 It allows for a recent, large,
representative longitudinal cohort of children observing
current UK practice.
We also acknowledge some weaknesses. First, the
CPRD only registers prescriptions issued by the
general practitioners and not actual drug dispensation
or consumption by the patient, nor does it register
prescriptions issued in secondary care by child psychia-
trists and paediatricians. However, our intention was to
report trends in prescribing patterns, and additionally
the extensive repeat prescribing we saw suggests con-
sumption. The lack of accurate information on the
exact age of patients for 38% of children with month
of birth missing and exact dates for none may have
introduced imprecision in the calculation of the
number of children that received prescriptions of
ADHD drugs under the licensed age (6 years old for
atomoxetine and methylphenidate). However, our sen-
sitivity analysis showed that this phenomenon was
unlikely to explain the majority of off-label prescrip-
tions. Overall, off-label prescribing of ADHD drug in
children under 6 years old appeared to be relatively
low.
Our analysis of treatment persistence was based on
elapsed time between ﬁrst prescription and a gap of
more than 3 months of ADHD drug prescription. It is
possible that children with apparent treatment breaks
may have received prescriptions from hospital, specialists
or other institutions or even had suspended treatment
during holidays. In the UK, specialists initiate ADHD
prescriptions and continued prescribing and monitoring
is typically performed under shared-care arrangements
by General Practitioners as recommended by NICE.34 As
compliance was not assessed, it is also possible that chil-
dren’s prescriptions may have lasted longer. It is there-
fore possible that incidence and persistence were
underestimated.
CONCLUSIONS
Among other countries such as the USA, the
Netherlands and Germany, the UK shows one of the
lowest estimates in ADHD drug prescribing rates in chil-
dren. Although the prevalence and incidence of ADHD
drug use in children have substantially increased during
the past two decades, it seems that it may have reached a
plateau recently. Looking at overall persistence in pre-
scribing of ADHD drugs, children in the UK show the
highest rates of ADHD drug persistence compared to
other European countries and the US. These ﬁndings
may suggest that UK prescribing practice restricts the
choice of children receiving ADHD drugs ensuring a
better follow-up of these children.
Our study indicates a turning point in the patterns of
ADHD drug prescribing in children in the UK.
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